Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint

Executive Summary

There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.

You may also be interested in...



Novartis’ Tobramycin Inhalation Powder May Face Questions Over Study Endpoint

Novartis’ inhalation powder version of the antibiotic tobramycin appears to be much more convenient in treating Pseudomonas aeruginosa infections in cystic fibrosis patients than the currently marketed nebulized solution (Tobi), but the appropriateness of the FEV1 endpoint is likely to be a matter of dispute during advisory committee review.

Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop

Quality-of-life metrics deserve consideration in addition to lung function in the development of aerosolized antimicrobials, researchers say.

Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor

Gilead Sciences will price its cystic fibrosis drug Cayston at an 8 percent premium to its competitor, Novartis' TOBI (tobramycin)

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel